Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | GAA | P10253 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16054062 | 0.90 | ALDH1A1 (0.64) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL6414184 | 0.89 | ALDH1A1 (0.74) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL20597980 | 0.87 | GAA (0.72) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL11287512 | 0.87 | GAA (0.72) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL22767195 | 0.87 | GAA (1.00) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL30501408 | 0.87 | GAA (0.72) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL32660033 | 0.87 | GAA (0.72) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL14313743 | 0.87 | ALDH1A1 (0.72) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL16982491 | 0.87 | ALDH1A1 (0.72) | ALDH1A1GAAKDM4EKMT2AMEN1 | |
| SCHEMBL2944851 | 0.87 | ALDH1A1 (1.00) | ALDH1A1GAAKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217551-B | Substituted indazole or azaindazole compounds and application thereof | 河南中医药大学 | 2024-07-30 | — | — | CN | disclosed |
| WO-2023242228-A1 | 4-SUBSTITUTED (1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLES AS BUB1 INHIBITORS USEFUL FOR TREATING CANCERS | UNIVERSITEIT LEIDEN (NL) | 2023-12-21 | — | — | WO | disclosed |
| EP-4293019-A1 | 4-SUBSTITUTED (1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLES AS BUB1 INHIBITORS USEFUL FOR TREATING CANCERS | Netherlands Translational Research Center Holding B.V. (NL) | 2023-12-20 | — | — | EP | disclosed |
| CN-113214287-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2023-10-20 | — | — | CN | disclosed |
| CN-116217551-A | Substituted indazole or azaindazole compounds and application thereof | 河南中医药大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-112047932-B | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| US-4312873-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1982-01-26 | — | — | US | disclosed |
| US-4191764-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1980-03-04 | — | — | US | disclosed |
| US-4139626-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059832-B2 | HPK1 inhibitors and methods of using same | PDXK, PDK3, PDK2 | ALDH1A1 2442/4885GAA 3453/4885KDM4E 941/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | ALDH1A1 1157/4885GAA 1133/4885KDM4E 828/4885 |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | ALDH1A1 2458/4885GAA 3500/4885KDM4E 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.